A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer [Research Articles]

This article is highlighted in the In This Issue feature, p. 539

Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., Faris, J. E., Eskens, F. A. L. M., Sharma, S., Yaeger, R., Lenz, H.-J., Wainberg, Z. A., Avsar, E., Chatter Tags: Research Articles Source Type: research